# TM CRUX UK Core Fund

GBP factsheet September 2022



## Fund Facts as at 30/09/22

### **Fund Objective**

The investment objective of the Fund is to achieve long-term growth, which should be seen as five years plus, through both capital appreciation and income generation.

#### Launch Date

B Acc Share Class launched: 28 March 2011

Structure

**Fund Size** £46.9m

**Performance comparator** IA UK All Companies

XD Dates Divider

Dividend Pay Dates 30-Nov, 31-May

| Market Capitalisation | (%)  |
|-----------------------|------|
| >£5bn                 | 44.3 |
| £500m - £5bn          | 39.2 |
| <£500m                | 13.0 |

| Charges (%)      | Initial | OCF  |
|------------------|---------|------|
| B Class<br>(GBP) | Nil     | 0.75 |

| Minimum Investment |      |  |  |
|--------------------|------|--|--|
| B Class (GBP)      | £100 |  |  |
| B Class (GBP)      | £100 |  |  |


GB00B5839S67 (B Acc)



| Top 10 Holdings          | %   |
|--------------------------|-----|
| Shell                    | 7.5 |
| Serco                    | 5.1 |
| Standard Chartered       | 4.9 |
| British American Tobacco | 4.8 |
| Glencore                 | 4.8 |
| Smith & Nephew           | 4.4 |
| Barclays                 | 4.4 |
| Aviva                    | 4.1 |
| Whitbread                | 3.9 |
| GSK                      | 3.7 |
| Total Holdings           | 30  |

| Top 10 Sectors                                    | %    |
|---|------|
| Banks   | 12.9 |
| Materials   | 9.4  |
| Retailing   | 8.3  |
| Food, Beverage & Tobacco                          | 7.6  |
| Energy  | 7.5  |
| Insurance   | 7.2  |
| Software & Services                               | 6.2  |
| Pharmaceuticals, Biotechnology<br>& Life Sciences | 6.1  |
| Capital Goods                                     | 5.9  |
| Health Care Equipment &<br>Services               | 5.8  |
| Cash  | 3.5  |

Source: CRUX Asset Management.



Source: as at 30 September 2022.  $\ensuremath{\mathbb{C}}$  2022 FE. All Rights Reserved. Total return, Bid-bid in GBP, net income reinvested.

Note: These figures refer to the past and past performance is not a reliable indicator of future results.

### Percentage Growth, from launch of B Class (28 March 2011) to 30 September 2022

# TM CRUX UK Core Fund



| $\sim$   |      | 1.    |
|----------|------|-------|
| $( \cap$ | ntin | iued  |
|          |      | iucu, |

| Disc Yr Perf* (%)          | YTD    | 2021  | 2020   | 2019  | 2018   | 2017  |
|----------------------------|--------|-------|--------|-------|--------|-------|
| TM CRUX UK Core Fund B Acc | -3.1%  | 15.1% | -10.0% | 22.8% | -7.0%  | 8.1%  |
| IA UK All Companies        | -17.2% | 17.2% | -6.0%  | 22.2% | -11.2% | 14.0% |

Disc Yr Perf\* (Discrete Year Performance)

Source: as at 30 September 2022. © 2022 FEFundinfo. All Rights Reserved. Total return, Bid-bid in GBP, net income reinvested. Discrete performance data may change due to final dividend information being received after quarter end.

Note: These figures refer to the past and past performance is not a reliable indicator of future results.



Richard Penny Fund Manager

MSCI ESG RATINGS

CCC B BB BBB A AAA Produced by MSCI ESG Research as of (30 September 2022)

MCSI ESG Research LLC's ("MSCI ESG") Fund Metrics and Ratings (the "information") provide environmental social and governance data with respect to underlying securities within more than 31,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The information is provided "as is" and the user of the Information assumes the entire risk of any use

#### Important Information

Please note the views, opinions and forecasts expressed in this document are based on CRUX's research and analysis at the time of publication. Before entering into an investment agreement in respect of an investment referred to in this document, you should consult your own professional and/or investment adviser. TM CRUX UK Core Fund (the 'Fund') is a sub-fund of TM CRUX Funds ICVC (the 'Company'). The Company is an investment company with variable capital and is a UCITS Scheme. It is incorporated under the Open-Ended Investment Companies Regulations 2001 ('OEIC Regulations') in England and Wales under registry number IC000065. The Company is regulated by the FCA and was authorised on 13 March 2000. The FP CRUX UK Fund was renamed the TM CRUX UK Core Fund in December 2019. This information is directed at persons residing in the United Kingdom only. The KIID and Fund Prospectus and other documentation related to the Scheme, are available from the CRUX website www.cruxam.com. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. If you invest through a third party provider you are advised to consult them directly as charges, performance and terms and conditions may differ materially to those shown on this document.

Please note: Due to rounding the figures in the holdings breakdown may not add up to 100%. Unless otherwise indicated all figures sourced from Financial Express, Datastream, State Street and CRUX Asset Management Ltd. Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.

This document has been approved under Section 21 of the Financial Services and Markets Act 2000 by CRUX Asset Management Ltd. This document is issued by CRUX Asset Management Ltd which is registered in England and Wales (Company no. 08697189) and whose registered address is 48 Pall Mall, London, SW1Y 5JG. It is authorised and regulated by the Financial Conduct Authority (FRN 623757).

These figures refer to the past and past performance is not a reliable indicator of future results.

The Authorised Corporate Director is Thesis Unit Trust Management Limited, Exchange Building, St John's Street, Chichester, West Sussex, PO19 1UP. Authorised and regulated by the Financial Conduct Authority.